This drug candidate is intended for the prophylactic protection against food allergens and is currently in Phase IIb clinical development. Pursuant to the agreement, GSK will obtain the global rights (excluding Chinese Mainland, Hong Kong, Macau, and Taiwan) to develop and commercialize ozureprubart. Concurrently, GSK will assume the responsibility for future success-based milestone and royalty payments owed to RAPT's partner, Shanghai Jeyou Pharmaceutical Co., Ltd.

The journey of innovative drug development, from target discovery and drug design through clinical trials to commercialization, typically spans a decade, with a failure rate exceeding 90%. This is the current industry reality—it cannot be compressed, shortened, or "financial engineered." While AI algorithms are increasingly being applied to drug discovery, to date, no drug fully designed by AI has received market approval.

At JPM 2026, 24 Chinese innovative biopharmaceutical companies presented in the main conference and Asia-Pacific sessions, while an even greater number completed significant licensing deals with multinational corporations during the event. In key focus areas at JPM 2026, such as antibody-drug conjugates (ADCs), metabolic diseases, and cell and gene therapies, Chinese innovative drugs have become an indispensable source of value.

VCBeat has learned that YH01, a domestically developed novel oncolytic virus drug independently researched and developed by Beijing Yinmei Future Biomedical Technology Co., Ltd. (hereinafter referred to as "Yinmei Future"), has recently disclosed the phase Ⅱ clinical trial progress for high-risk Non-Muscle Invasive Bladder Cancer (NMIBC). Preliminary data show that among 11 evaluable patients, 9 achieved complete response (CR), with a CR rate of 81.8%, which provides a new biological treatment pathway exploration for the clinical challenge of bacillus calmette-guerin (BCG) treatment failure. In particular, among patients who received 6 doses, the 3-month CR rate reached 87.5%, and the 6-month CR rate reached 80%.

Precision is a global leader in invasive brain-computer interfaces and a major competitor to the well-known Neuralink, owned by Musk. Its Layer 7 brain-computer interface, which utilizes a high-resolution cortical electrode array, received FDA approval in April of last year. It can be implanted into patients' brains for up to 30 days, enabling individuals with severe paralysis to control electronic devices such as computers and smartphones through their thoughts.

Recently, disease control and prevention centers across China have rolled out subsidized vaccination initiatives for herpes zoster. Two approved herpes zoster vaccines in China have undergone significant price reductions: the second dose of GSK's imported recombinant herpes zoster vaccine (brand name: Shingrix®) is now offered free of charge, while the domestic herpes zoster live attenuated vaccine produced by BCHT (brand name: Gan Wei) is available at a discount of 30% to 80%.

On the opening day of the A-share market in 2026 (January 5), Chinese brain-computer interface concept stocks collectively opened higher. Among them, Beoka surged over 29.98%, while SanBo, Xiangyu Medical, Mehow Medical, Apon Medical, Chieftain, and Vishee Medical all hit the 20% daily price limit. Innovative Medical and Thalys Medical rose over 10%, with Biotest and Vishee Medical, among others, also gaining. As of the market close that day, the stock prices continued to exhibit a high-opening-and-high-trading trend, reflecting strong market expectations for the commercial prospects of brain-computer interface technology.

ZG006 is a novel trispecific T-cell engager targeting two distinct DLL3 epitopes and CD3. It represents the world's first DLL3-targeting trispecific antibody (CD3/DLL3/DLL3) with best-in-class potential. Currently, it is in late-stage clinical development for the treatment of small cell lung cancer (Phase III) and other DLL3-expressing malignancies.

This trend not only marks the transition of bispecific antibody technology from a niche field to a mainstream focus but also signals its potential to replace traditional monoclonal antibodies and antibody-drug conjugates as the cornerstone of next-generation biopharmaceutical development.

With revenue from drug discovery and pipeline development accounting for over 90% of its total income and its gross margins reaching 90%, how has this company—founded seven years ago and having completed eight funding rounds—convinced the secondary market to assign a premium valuation to its "AI-driven drug discovery platform and AI-empowered pipeline"?

Novartis' Pluvicto, a key nuclear medicine product, generated sales of $1.392 billion in 2024, a year-on-year increase of 42%. In the first three quarters of 2025, its revenue reached $1.389 billion, nearly matching its full-year 2024 sales and representing a 33% growth. At the 2025 J.P. Morgan Healthcare Conference, Novartis projected that Pluvicto's peak sales are expected to exceed $5 billion.

As outlined in its prospectus, QingSong Health primarily operates two major business segments: providing individuals and corporate clients with various health-related services, including health education, digital medical research support, and comprehensive health service packages; and offering insurance-related services to support users' healthcare expenditures and meet their coverage needs.

NouvNeu001 is now the first iPSC product globally to hold both RMAT and Fast Track Designation (FTD) status, the latter having been granted on August 15, 2025. This rapid sequential recognition highlights the FDA's strong confidence in its clinical data.

Under the terms of the agreement, MultiValent has been granted the exclusive rights to develop and commercialize CBP-1018 in all markets outside of Greater China. In return, CBP will receive an upfront payment of USD 20 million and a 20% equity stake in MultiValent. Additionally, CBP is eligible to receive future milestone payments potentially totaling up to approximately USD 2 billion, tied to development, regulatory, and commercial achievements, as well as tiered royalties on net sales.

Leveraging its leading expertise in small-molecule technology, Jacobio has become one of the companies with the most advanced clinical progress in this field. This collaboration extends beyond a traditional asset licensing agreement to include co-development within the Chinese market, marking the entry into a new phase of partnership models between Chinese innovative drug companies and global pharmaceutical giants.

Since its inception, B&K Corporation has consistently focused on discovering, developing, and commercializing therapies for wound healing, particularly platelet-derived growth factor (PDGF) drugs. PDGF is one of the growth factors secreted by platelets after injury, which promotes (among other functions) the formation of new blood vessels, modulates inflammation, and stimulates cell proliferation and migration, ultimately accelerating wound healing.

In 2010, Acrobiosystems entered the market focusing on recombinant proteins and related biological reagents, precisely targeting the upstream segments of the biopharmaceutical R&D chain from the outset. The company aimed to become a core tool supplier for fundamental research and early-stage drug development.

On December 7, Eli Lilly announced new results from the Phase III BRUIN CLL-314 clinical trial. This study aimed to evaluate the efficacy of the non-covalent (reversible) BTK inhibitor Jaypirca® (pirtobrutinib) compared to the covalent BTK inhibitor Imbruvica® (ibrutinib) in patients with treatment-naïve or previously untreated (without prior BTK inhibitor therapy) chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL).

CSPC Innovation Pharmaceutical's caffeine products are currently exported to 65 countries and regions worldwide, primarily serving the North American and European markets. Leveraging consistent product quality, cost advantages from scaled production, and a robust supply chain system, CSPC Innovation Pharmaceutical has established stable cooperative relationships with leading international beverage industry clients.

Evidently, within the medical device sector influenced by various market and policy factors, ophthalmic surgical microscopes have emerged as one of the most resilient and strongly growing sub-segments in China. While the increase in winning bid volume for these devices is partly driven by rising surgical demand, from a product perspective, why are ophthalmic surgical microscopes selling so well?